Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan
While this application requires further clinical investigation, some studies have shown the peptide stimulating cartilage cell proliferation and demonstrating potential benefits for osteoarthritis treatment
As of April 22, 2026, it was removed from FDA Category 2, but the FDA's Pharmacy Compounding Advisory Committee will not consider it for the 503A bulks list until the July 23, 2026 meeting
For example, insufficient B12 may result in methyl folate not being able to give up its methyl group and it gets stuck in-between the two cycles, with MTR not being able to do its part
The injection procedure typically takes place in a surgery center, hospital, or a physician's clinic